TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04142008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walk with Me app
Description: For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
Study: NCT03507478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPI1000013
Description: Foam insole
Study: NCT00196131

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: morphine
Description: only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
Study: NCT03095573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral-viewing CapsoCam device
Description: Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axial-viewing capsule
Description: Small bowel capsule endoscopy examination with the Axial-viewing capsule device
Study: NCT03822221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 85º and knee at 20º
Description: With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 85º and knee at 60º
Description: With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 0º and knee at 20º
Description: With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MVIC and NMES with hip at 0º and knee at 60º
Description: With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
Study: NCT01764295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Study: NCT03783728

Intervention type: DRUG
Intervention: Rifapentine 600 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study: NCT01764295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study: NCT03914625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study: NCT03783728

Intervention type: DRUG
Intervention: Isoniazid 900 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study: NCT01764295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03914625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02386735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three days prednisone 40mg, two days placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Five days prednisone 40mg.
Study: NCT03781674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 400mg
Description: Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 200mg
Description: Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
Study: NCT03783728

Intervention type: DRUG
Intervention: Pyridoxine 50 mg orally
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study: NCT00976950

Intervention type: DRUG
Intervention: Tipranavir

Intervention type: DRUG
Intervention: ritonavir
Description: low-dose
Study: NCT03991559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manganese Chloride
Description: Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manganese Chloride
Description: Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
Study: NCT03781674

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to progesterone 200mg
Description: Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
Study: NCT03875963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic loaded bone filler
Description: Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
Study: NCT03781674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to progesterone 200mg
Description: Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to progesterone 400mg
Description: Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
Study: NCT02771405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg orally once daily
Study: NCT02423798

Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose sensor (Enlite)
Description: This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
Study: NCT03991559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 antibody
Description: Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
Study: NCT02771405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclatasvir
Description: Daclatasvir 60 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Description: Ledipasvir 90 mg orally once daily
Study: NCT04330209

Intervention type: OTHER
Intervention: weight loss diets
Description: The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results

Intervention type: OTHER
Intervention: weight loss diets
Description: The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
Study: NCT03991559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 antibody
Description: Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Whether and which should be given depends on the treatment regimen before enrollment.
Study: NCT01131052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: glargine once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
Study: NCT01063972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centralized disease management (CDM)
Description: Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (C)
Description: Counseling (C) arm will receive counseling without the care coordination services.
Study: NCT01131052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: glulisine given as needed before meals
Study: NCT03991559

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Whether and which should be given depends on the treatment regimen before enrollment.
Study: NCT01442532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (30 mg)
Description: Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (10 mg)
Description: Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (3 mg)
Description: Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral use, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and JNJ-38518168
Description: Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
Study: NCT04561245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study: NCT04248192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DD HST-NEETs
Description: HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
Study: NCT03303040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of hemidiaphragm
Description: Electrical impulses
Study: NCT00772382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
Study: NCT01478438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novilase Interstitial Laser Therapy
Description: Image guided Interstitial Laser Ablation of breast tumors
Study: NCT01948141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: Given PO
Study: NCT02421744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Oriented Circuit Training
Description: TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Onset TOCT
Description: The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
Study: NCT04113096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibenzyl trisulphide capsules
Description: 20 mg once daily for 6 months
Study: NCT03895944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells -iv low dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells -iv middle dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells - iv high dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
Study: NCT02071264

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HIV/STI intervention
Description: The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
Study: NCT04113096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibenzyl trisulphide capsules
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibenzyl trisulphide capsules
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibenzyl trisulphide capsules
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage IV Breast Cancer Placebo
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage IV: Colon Cancer Placebo
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervical Cancer Stage IV Placebo
Description: 20 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cancer of the Prostate Placebo
Description: 20 mg once daily for 6 months
Study: NCT04114786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed mask
Description: After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic mask
Description: Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
Study: NCT02805790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elamipretide
Description: 4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 weeks of treatment with placebo administered once daily subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of treatment with placebo administered once daily subcutaneously
Study: NCT02263014

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
Study: NCT00644839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 alone in period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Adminstration of CP-945,598 with omeprazole in period 2
Study: NCT02172014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam and fentanyl citrate infusion
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam and normal saline infusion
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Study: NCT04065321

Intervention type: PROCEDURE
Intervention: PET-CT examination
Description: All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
Study: NCT03289468

Intervention type: DIAGNOSTIC_TEST
Intervention: Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler
Description: The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.

Intervention type: DIAGNOSTIC_TEST
Intervention: Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler
Description: The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
Study: NCT02191319

Intervention type: DRUG
Intervention: Viramune®
Study: NCT04065321

Intervention type: PROCEDURE
Intervention: Peripheral blood detection
Description: All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
Study: NCT02466828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme®
Description: Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.